184 related articles for article (PubMed ID: 25916217)
1. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma.
Ozturk H
Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217
[TBL] [Abstract][Full Text] [Related]
2. Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography.
Öztürk H
Cancer Res Treat; 2015 Oct; 47(4):834-43. PubMed ID: 25687863
[TBL] [Abstract][Full Text] [Related]
3. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.
Jadvar H; Kherbache HM; Pinski JK; Conti PS
Clin Nephrol; 2003 Dec; 60(6):395-400. PubMed ID: 14690256
[TBL] [Abstract][Full Text] [Related]
5. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
6. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
7. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
8. Role of
Ozturk H
Rep Pract Oncol Radiother; 2023; 28(6):728-736. PubMed ID: 38515818
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of
Öztürk H; Karapolat I
Exp Ther Med; 2015 Mar; 9(3):717-724. PubMed ID: 25667618
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
12. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis.
Ma H; Shen G; Liu B; Yang Y; Ren P; Kuang A
Nucl Med Commun; 2017 Feb; 38(2):156-163. PubMed ID: 27824726
[TBL] [Abstract][Full Text] [Related]
14. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
15. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
[TBL] [Abstract][Full Text] [Related]
16. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
[TBL] [Abstract][Full Text] [Related]
17. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
19. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
20. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
